Protocol Library - Altai Oncology Software

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions

Over 1,000 cancer treatment protocols

Medical Oncology, Hematology, Bone Marrow Transplantation

With administration details, lab parameters, indications, and summarized references

Updated monthly to include latest approvals and major papers

Reviewed by Medical Oncologists and Hematologists

Hodgkin Lymphoma

New Protool: Nivolumab-AVD in Hodgkin Lymphoma

Ulas D. Bayraktar, MD

Breast Cancer

New Indication: Adjuvant Abemaciclib in HR+ Breast Cancer

Ulas D. Bayraktar, MD

Nervous System Tumor

New Indication: Dabrafenib and Trametinib in bRAF V600E Mutant Glioma

Ulas D. Bayraktar, MD

Hepatocellular Carcinoma

New Indication: Adjuvant Atezolizumab – Bevacizumab in HCC

Ulas D. Bayraktar, MD

Mantle cell lymphoma

New Drug: Pirtobrutinib in Mantle Cell Lymphoma

Ulas D. Bayraktar, MD

Diffuse Large B Cell Lymphoma

New Drug: Glofitamab in Large B-Cell Lymphoma

Ulas D. Bayraktar, MD

Skin Cancer (Other than Melanoma)

New Drug: Retifanlimab in Advanced Merkel Cell Carcinoma

Ulas D. Bayraktar, MD

Breast Cancer

New Reference: Trastuzumab Deruxtecan for her2-Positive Breast Cancer

Ulas D. Bayraktar, MD

Soft Tissue Sarcoma

New Protocol: Nivolumab and Trabectedin in Advanced Soft Tissue Sarcoma

Ulas D. Bayraktar, MD

Hodgkin Lymphoma

New Protool: Nivolumab-AVD in Hodgkin Lymphoma

Phase III, randomized, controlled study (SWOG S1826) Previously untreated pts were ≥12 years (y) with stage 3-4 HL N-AVD (n=489) vs. BV-AVD (n=487)

New Indication: Adjuvant Abemaciclib in HR+ Breast Cancer

Phase III, randomized, open-label trial (monarchE) Hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence Abemaciclib + ET (n=280

Nervous System Tumor

New Indication: Dabrafenib and Trametinib in bRAF V600E Mutant Glioma

Open-label, single-arm, phase 2, basket trial BRAFV600E mutation-positive high- low-grade glioma Prior radiotherapy and chemotherapy or chemoradiotherapy for high grade glioma Dabr

Hepatocellular Carcinoma

New Indication: Adjuvant Atezolizumab – Bevacizumab in HCC

Phase III, randomized, controlled, multicenter, open-label trial (İMbrave050) HCC pts at high risk of recurrence following resection or ablation. Atezolizumab + Bevacizumab q21 (n

Mantle cell lymphoma

New Drug: Pirtobrutinib in Mantle Cell Lymphoma

Open-label, multicenter, single-arm trial (BRUIN) Mantle cell lymphoma previously treated with a BTK inhibitor Pirtobrutinib (n=120)

Diffuse Large B Cell Lymphoma

New Drug: Glofitamab in Large B-Cell Lymphoma

Phase I-II, open-label, multicenter study Relapse or refractory large cell lymphoma Glofitamab (n=132)

Skin Cancer (Other than Melanoma)

New Drug: Retifanlimab in Advanced Merkel Cell Carcinoma

Open-label, multicenter, single-arm, phase 2 study Treatment naïve metastatic or recurrent locally advanced MCC Retifanlimab q28 (n=65)

New Reference: Trastuzumab Deruxtecan for her2-Positive Breast Cancer

Phase III, randomized, controlled, multicenter, open-label trial (DESTINY-Breast-02) HER2-positive, previously received trastuzumab-emtansine, unresectable or metastatic breast can

Soft Tissue Sarcoma

New Protocol: Nivolumab and Trabectedin in Advanced Soft Tissue Sarcoma

Prospective, explorative, two-group, non-randomized, phase II trial (NITraSarc) Advanced, previously treated lipo-leiomyosarcoma (Group A: GA) (n=43) and non-L-sarcomas (Group B:

Our Solutions

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols

Altai Oncology Suite

Our premiere, CE-marked, Windows application designed for cancer centers

Altai Oncology App

Easiest access to our protocol library on your hands

Altai Chemo Planner

Core features of Altai Oncology Suite for the solo Oncologist/Hematologist

Articles

Computerized Chemotherapy Order Entry

The Power of a Protocol Library: Standardizing Oncology Care Across Institutions

Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …

From Protocol to Pharmacy: Ensuring Seamless Chemotherapy Order Handover

Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.

Back to top Drag